Anticoagulation and Valvular Heart Disease: Comprehensive Management Guide
I. General Anticoagulation in Atrial Fibrillation
For patients with atrial fibrillation, direct oral anticoagulants (DOACs) are preferred over warfarin except in patients with mechanical heart valves or moderate-to-severe mitral stenosis 1, 2.
CHA₂DS₂-VASc Score for Stroke Risk Stratification
The CHA₂DS₂-VASc score guides anticoagulation decisions in AF:
- CHA₂DS₂-VASc ≥2: Anticoagulation recommended 1
- CHA₂DS₂-VASc = 1: Anticoagulation should be considered 1
- CHA₂DS₂-VASc = 0: No anticoagulation needed
Scoring components:
- Congestive heart failure: 1 point
- Hypertension: 1 point
- Age ≥75 years: 2 points
- Diabetes mellitus: 1 point
- Stroke/TIA/thromboembolism: 2 points
- Vascular disease (prior MI, PAD, aortic plaque): 1 point
- Age 65-74 years: 1 point
- Sex category (female): 1 point
HAS-BLED Score for Bleeding Risk Assessment
Critical caveat: Bleeding risk scores should NOT be used to decide whether to start or withhold anticoagulation 1. Instead, use HAS-BLED to identify modifiable bleeding risk factors and determine monitoring intensity.
Scoring components:
- Hypertension (uncontrolled, >160 mmHg systolic): 1 point
- Abnormal renal function (dialysis, transplant, Cr >2.6 mg/dL): 1 point
- Abnormal liver function (cirrhosis or bilirubin >2x normal + AST/ALT >3x normal): 1 point
- Stroke history: 1 point
- Bleeding history or predisposition: 1 point
- Labile INR (if on warfarin, <60% time in therapeutic range): 1 point
- Elderly (age >65): 1 point
- Drugs (antiplatelet agents, NSAIDs) or alcohol (≥8 drinks/week): 1-2 points
Score ≥3 indicates high bleeding risk—address modifiable factors but do not withhold anticoagulation if indicated 1.
II. Oral Anticoagulants: Drug-Specific Details
Warfarin (Vitamin K Antagonist)
Indications:
- Mechanical heart valves (ALL types) 2
- Moderate-to-severe mitral stenosis with AF 3
- Bioprosthetic valves (alternative to DOACs) 2
Dosing:
- Initial: 2-5 mg daily (lower doses for elderly, debilitated, or those with CYP2C9/VKORC1 genetic variants) 3
- Maintenance: 2-10 mg daily, adjusted to INR target 3
- Target INR varies by indication:
- Mechanical bileaflet AVR (e.g., St. Jude Medical): INR 2.5 (range 2.0-3.0) 3
- Mechanical tilting disk or bileaflet MVR: INR 3.0 (range 2.5-3.5) 3
- Mechanical caged ball/disk valves: INR 3.0 (range 2.5-3.5) + aspirin 75-100 mg daily 3
- Bioprosthetic valves: INR 2.5 (range 2.0-3.0) for 3-6 months post-op 3
- Non-valvular AF: INR 2.5 (range 2.0-3.0) 3
Goal: Keep INR in therapeutic range >70% of the time 1.
Key Drug Interactions:
- Increase INR: Amiodarone, azole antifungals, macrolide antibiotics, metronidazole, sulfonamides, SSRIs, NSAIDs
- Decrease INR: Rifampin, carbamazepine, phenytoin, St. John's wort, vitamin K-rich foods (leafy greens)
Pearls:
- Avoid loading doses—increase hemorrhagic complications without faster protection 3
- INR >4.0 provides no additional benefit and increases bleeding risk 3
- Fluctuating INR increases complication rates 2
Dabigatran (Direct Thrombin Inhibitor)
Indications:
- Non-valvular AF 1
Absolute Contraindications:
- Mechanical heart valves (Class III Harm recommendation) 2
- Moderate-to-severe mitral stenosis
Dosing:
- Standard: 150 mg twice daily
- Reduced: 110 mg twice daily (age ≥80, concurrent P-gp inhibitors, high bleeding risk)
- Renal adjustment: CrCl 30-50 mL/min: consider 110 mg BID; CrCl <30 mL/min: contraindicated
Drug Interactions:
- P-glycoprotein inhibitors (increase dabigatran levels): Dronedarone, ketoconazole, verapamil, amiodarone
- P-glycoprotein inducers (decrease levels): Rifampin, St. John's wort
Pearls:
- Only DOAC with specific reversal agent (idarucizumab) 4
- Take with food to reduce dyspepsia
- Store in original container (moisture-sensitive)
Edoxaban (Factor Xa Inhibitor)
Indications:
- Non-valvular AF 1
Contraindications:
- Mechanical heart valves
- Moderate-to-severe mitral stenosis
- CrCl >95 mL/min (paradoxically increased stroke risk in AF)
Dosing:
- Standard: 60 mg once daily
- Reduced: 30 mg once daily if:
- CrCl 15-50 mL/min
- Body weight ≤60 kg
- Concurrent P-gp inhibitors (verapamil, quinidine, dronedarone)
Drug Interactions:
- Similar to dabigatran (P-gp interactions)
Pearls:
- Once-daily dosing improves adherence
- No specific reversal agent available
Apixaban (Factor Xa Inhibitor)
Indications:
Contraindications:
- Mechanical heart valves
- Moderate-to-severe mitral stenosis
Dosing:
- Standard: 5 mg twice daily
- Reduced: 2.5 mg twice daily if ≥2 of the following:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
Drug Interactions:
- Strong dual CYP3A4 and P-gp inhibitors (ketoconazole, ritonavir): avoid or reduce dose
- Strong dual inducers (rifampin, phenytoin): avoid
Pearls:
- Lowest bleeding rates among DOACs in meta-analyses
- No specific reversal agent (andexanet alfa available but limited data)
Rivaroxaban (Factor Xa Inhibitor)
Indications:
- Non-valvular AF 1
Absolute Contraindications:
- Mechanical heart valves
- Moderate-to-severe mitral stenosis
- Bioprosthetic TAVI + rivaroxaban 10 mg + aspirin is CONTRAINDICATED (Class III Harm) 2
Dosing:
- Standard: 20 mg once daily with evening meal
- Reduced: 15 mg once daily if CrCl 15-50 mL/min
Drug Interactions:
- Similar to apixaban (CYP3A4 and P-gp interactions)
Pearls:
- Must take with food to ensure absorption
- Once-daily dosing
- No specific reversal agent
III. Valvular Heart Disease: Diagnosis and Medical Management
A. Aortic Stenosis (AS)
Diagnosis:
- Echocardiography: Mean gradient >40 mmHg, peak velocity >4 m/s, valve area <1.0 cm²
- Symptoms: Angina, syncope, dyspnea (indicate severe AS)
Medical Management:
- No role for anticoagulation in isolated AS without AF
- Treat AF per CHA₂DS₂-VASc score (DOACs preferred) 1
- Avoid vasodilators in severe symptomatic AS
B. Aortic Regurgitation (AR)
Diagnosis:
- Echocardiography: Regurgitant volume >60 mL/beat, regurgitant fraction >50%, effective regurgitant orifice >0.3 cm²
- Symptoms: Dyspnea, orthopnea, angina
Medical Management:
- No anticoagulation for isolated AR without AF
- Vasodilators (ACE inhibitors, ARBs) for chronic severe AR with LV dysfunction
- Treat AF per CHA₂DS₂-VASc score (DOACs preferred) 1
C. Mitral Stenosis (MS)
Diagnosis:
- Echocardiography: Valve area <1.5 cm² (severe <1.0 cm²), mean gradient >5 mmHg
Medical Management:
- Moderate-to-severe MS + AF: Warfarin ONLY (DOACs contraindicated) 1, 3
- Target INR 2.5 (range 2.0-3.0) 3
- Rate control with beta-blockers or diltiazem/verapamil (if LVEF >40%) 1
Critical pitfall: DOACs are NOT validated in moderate-to-severe MS—always use warfarin 1, 6.
D. Mitral Regurgitation (MR)
Diagnosis:
- Echocardiography: Regurgitant volume >60 mL/beat, regurgitant fraction >50%, effective regurgitant orifice >0.4 cm²
Medical Management:
- No anticoagulation for isolated MR without AF
- Treat AF per CHA₂DS₂-VASc score (DOACs preferred) 1
- Vasodilators for chronic severe MR with LV dysfunction
IV. Prosthetic Valves: Postoperative Antithrombotic Management
A. Transcatheter Aortic Valve Replacement (TAVI/TAVR)
Without AF:
- Aspirin 75-100 mg daily alone is reasonable (Class IIa) 2
- Alternative: Dual antiplatelet therapy (aspirin 75-100 mg + clopidogrel 75 mg) for 3-6 months may be reasonable if low bleeding risk (Class IIb) 2
- Alternative: Warfarin INR 2.5 (range 2.0-3.0) for 3 months may be reasonable if low bleeding risk (Class IIb) 2
With AF:
- DOAC monotherapy preferred (apixaban, rivaroxaban, edoxaban, or dabigatran per standard AF dosing) 5, 7
- Warfarin INR 2.5 (range 2.0-3.0) is alternative 2
CONTRAINDICATED:
- Rivaroxaban 10 mg + aspirin (Class III Harm—increased bleeding without benefit) 2
B. Surgical Bioprosthetic Valve Replacement
Without AF:
- Aspirin 75-100 mg daily is reasonable (Class IIa) 2
- Warfarin INR 2.5 (range 2.0-3.0) for 3-6 months is reasonable if low bleeding risk (Class IIa) 2
With AF:
- DOACs preferred (standard AF dosing per CHA₂DS₂-VASc score) 1, 5, 7
- Recent real-world data show DOACs have similar efficacy and safety to warfarin in bioprosthetic valves with AF 5
- Warfarin INR 2.5 (range 2.0-3.0) is alternative 2
C. Surgical Mechanical Valve Replacement
ALL mechanical valves require lifelong warfarin—DOACs are CONTRAINDICATED 2.
1. Mechanical Aortic Valve Replacement (AVR)
Bileaflet valve (e.g., St. Jude Medical) in aortic position:
Tilting disk or older-generation valves:
- Warfarin INR 3.0 (range 2.5-3.5) 3
Caged ball or caged disk valves:
- Warfarin INR 3.0 (range 2.5-3.5) + aspirin 75-100 mg daily 3
Addition of aspirin:
- May be considered if low bleeding risk and indication for antiplatelet therapy (Class IIb) 2
2. On-X Mechanical Aortic Valve
Special lower INR target for On-X AVR:
- After ≥3 months post-op, if NO thromboembolic risk factors: Warfarin INR 1.5-2.0 + aspirin 75-100 mg daily may be reasonable (Class IIb) 2
- If ANY thromboembolic risk factors present: Standard INR 2.5 (range 2.0-3.0) 2
Thromboembolic risk factors include:
- Atrial fibrillation
- Left atrial enlargement
- LV dysfunction (LVEF <35%)
- Prior thromboembolism
- Hypercoagulable state
3. Mechanical Mitral Valve Replacement (MVR)
ALL mechanical mitral valves:
Addition of aspirin:
- May be considered if low bleeding risk and indication for antiplatelet therapy (Class IIb) 2
D. Valve-in-Valve (ViV) Procedures
Transcatheter valve within failed bioprosthetic valve:
Without AF:
- Aspirin 75-100 mg daily 2
- Consider dual antiplatelet therapy for 3-6 months if low bleeding risk
With AF:
V. Miscellaneous Cardiac Procedures
A. Patent Foramen Ovale (PFO) Closure
Post-procedure anticoagulation:
- Dual antiplatelet therapy (aspirin 81-325 mg + clopidogrel 75 mg) for 1-6 months (most common regimen)
- Then aspirin 81-325 mg daily for at least 5 years
- If concurrent AF: Anticoagulation per CHA₂DS₂-VASc score (DOACs preferred) 1
B. Left Atrial Appendage Occlusion (LAAO/Watchman Device)
Post-procedure anticoagulation protocol:
Standard regimen:
- Warfarin INR 2.0-3.0 + aspirin 81-325 mg daily for 45 days post-implant
- At 45 days: TEE to assess device position and peridevice leak
- If adequate seal: Switch to dual antiplatelet therapy (aspirin + clopidogrel) for 6 months
- If peridevice leak: Continue warfarin
- After 6 months: Aspirin 81-325 mg daily indefinitely
Alternative regimen (if warfarin contraindicated):
- Dual antiplatelet therapy (aspirin + clopidogrel) for 6 months, then aspirin alone
If concurrent indication for anticoagulation (e.g., VTE):
- Continue anticoagulation per primary indication (DOACs acceptable) 1
C. Left Ventricular Assist Device (LVAD)
Anticoagulation is MANDATORY for all LVAD patients to prevent pump thrombosis:
Standard regimen:
- Intravenous heparin immediately post-op (start when chest tube drainage <50 mL/hr)
- Transition to warfarin within 24-72 hours
- Target INR 2.0-3.0 (specific target varies by device—HeartMate 3 typically 2.0-3.0)
- Add aspirin 81-325 mg daily once hemostasis achieved (typically post-op day 1-3)
Long-term:
- Warfarin INR 2.0-3.0 + aspirin 81-325 mg daily indefinitely (or until transplant/device explant)
Critical monitoring:
- Weekly INR initially, then every 1-2 weeks once stable
- Monitor for signs of pump thrombosis (rising LDH, hemolysis, decreased pump flows)
- DOACs are NOT validated in LVAD patients—warfarin is standard of care
If AF develops:
- Continue warfarin at LVAD target INR (do NOT switch to DOAC)
- Warfarin provides anticoagulation for both LVAD and AF
VI. Key Clinical Algorithms
Algorithm 1: Choosing Anticoagulant in AF
Does patient have mechanical valve or moderate-to-severe mitral stenosis?
- YES → Warfarin ONLY (target INR per valve type/position)
- NO → Proceed to step 2
Calculate CHA₂DS₂-VASc score:
- Score 0 (men) or 1 (women) → No anticoagulation
- Score 1 (men) or 2 (women) → Consider anticoagulation
- Score ≥2 (men) or ≥3 (women) → Anticoagulation recommended
If anticoagulation indicated, choose agent:
- Prefer DOAC (apixaban, rivaroxaban, edoxaban, or dabigatran) 1
- Use warfarin if:
- Patient preference
- Poor DOAC adherence anticipated
- CrCl <15 mL/min (or <30 for dabigatran)
- Cost prohibitive
Algorithm 2: Post-Valve Replacement Anticoagulation
Mechanical valve?
- YES → Warfarin lifelong (INR per valve type/position) 2
- NO → Proceed to step 2
Bioprosthetic valve—Does patient have AF?
Bioprosthetic valve without AF:
Algorithm 3: Managing Anticoagulation with Concurrent Antiplatelet Needs
Scenario: Patient on anticoagulation requires PCI or has ACS
Mechanical valve:
- Continue warfarin (target INR per valve type)
- Add aspirin 75-100 mg + clopidogrel 75 mg for minimum duration (1 month for bare metal stent, 3-6 months for drug-eluting stent)
- High bleeding risk: Consider aspirin alone with warfarin 2
AF on DOAC:
- Continue DOAC
- Add clopidogrel 75 mg (omit aspirin) for minimum duration (1-6 months depending on stent type and bleeding risk)
- Then DOAC + aspirin 75-100 mg for up to 12 months
- Then DOAC alone 1
Critical principle: Minimize triple therapy duration to reduce bleeding risk 1.